Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging artificial intelligence and genomic data to develop precision oncology therapies, has closed a registered direct offering that raised approximately $4 million in gross proceeds before fees and expenses. The offering consisted of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, priced at $1.09 per share. In a concurrent private placement, the company issued unregistered warrants to purchase up to an additional 3,669,725 shares at an exercise price of $1.09 per share, which could provide another $4 million in gross proceeds if fully exercised for cash. Rodman & Renshaw LLC served as the exclusive placement agent for the offering. The company plans to use the net proceeds for working capital and other general corporate purposes.
The capital infusion is significant for Lantern Pharma as it continues to advance its pipeline of AI-driven cancer therapies. The company's proprietary RADR artificial intelligence and machine-learning platform is designed to transform the cost, pace, and precision of oncology drug development by integrating large-scale genomic and biological data to identify patients most likely to benefit from its therapies and guide biomarker-driven clinical development. With this funding, Lantern can further its mission to bring more effective, targeted treatments to cancer patients. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more details on the offering, see the full press release at https://nnw.fm/a9u8A.
Investors and stakeholders can stay updated on Lantern Pharma's latest news and developments by visiting the company's newsroom at https://nnw.fm/LTRN. The announcement was distributed via NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. Through InvestorWire, IBN provides access to a vast network of wire solutions, and it also offers editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers, among other corporate communications solutions. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
This financing comes at a pivotal time for Lantern Pharma as it seeks to differentiate itself in the competitive oncology landscape. The company's AI-native approach, which combines machine learning with genomic data, has the potential to significantly reduce the time and cost of drug development while improving patient outcomes. The additional funds will support ongoing clinical trials and further validation of the RADR platform. As the biopharma industry increasingly embraces AI-driven drug discovery, Lantern's progress will be closely watched by investors and peers alike. The successful closing of this offering not only strengthens the company's balance sheet but also signals confidence from institutional investors in its strategic direction. With a clear focus on precision oncology and a robust pipeline, Lantern Pharma is well-positioned to make meaningful contributions to cancer treatment.
